Zobrazeno 1 - 10
of 516
pro vyhledávání: '"Norikazu, Masuda"'
Autor:
Seock-Ah Im, Javier Cortes, David W. Cescon, Mastura Md Yusof, Hiroji Iwata, Norikazu Masuda, Toshimi Takano, Chiun-Sheng Huang, Chi-Feng Chung, Koichiro Tsugawa, Yeon Hee Park, Koji Matsumoto, Kenichi Inoue, Ava Kwong, Sherene Loi, Wei Fu, Wilbur Pan, Vassiliki Karantza, Hope S. Rugo, Peter Schmid
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract In the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus ch
Externí odkaz:
https://doaj.org/article/779d501670554a368c8218be67b35429
Autor:
Madoka Iwase, Yukari Taniyama, Yuriko N. Koyanagi, Yumiko Kasugai, Isao Oze, Norikazu Masuda, Hidemi Ito, Keitaro Matsuo
Publikováno v:
Journal of Epidemiology, Vol 34, Iss 8, Pp 387-392 (2024)
Background: Reproductive factors, such as age at menarche, are known to be associated with disease risk, but data on trends in these factors in Japan are limited. In this study, we investigated secular trends in reproductive factors and explored thei
Externí odkaz:
https://doaj.org/article/0dacdcf1538747da8848bdd27b35a471
Autor:
Shin Takahashi, Nobuaki Sato, Kouji Kaneko, Norikazu Masuda, Masaaki Kawai, Hisashi Hirakawa, Tadashi Nomizu, Hiroji Iwata, Ai Ueda, Takashi Ishikawa, Hiroko Bando, Yuka Inoue, Takayuki Ueno, Shinji Ohno, Makoto Kubo, Hideko Yamauchi, Masahiro Okamoto, Eriko Tokunaga, Shunji Kamigaki, Kenjiro Aogi, Hideaki Komatsu, Masahiro Kitada, Yasuaki Uemoto, Tatsuya Toyama, Yutaka Yamamoto, Toshinari Yamashita, Takehiro Yanagawa, Hiroko Yamashita, Yoshiaki Matsumoto, Masakazu Toi, Minoru Miyashita, Takanori Ishida, Fumiyoshi Fujishima, Satoko Sato, Takuhiro Yamaguchi, Fumiaki Takahashi, Chikashi Ishioka
Publikováno v:
Translational Oncology, Vol 48, Iss , Pp 102060- (2024)
The TP53 signature is considered a predictor of neoadjuvant chemotherapy (NAC) response and prognostic factor in breast cancer. The objective of this study was to confirm TP53 signature can predict pathological complete response (pCR) and prognosis i
Externí odkaz:
https://doaj.org/article/74d2b36fc35b41b88125efdc9ac30b6a
Autor:
Toshimi Takano, Mitsuya Ito, Takayuki Kadoya, Tomofumi Osako, Tomoyuki Aruga, Norikazu Masuda, Toshiko Miyaki, Naoki Niikura, Daisuke Shimizu, Yuichi Yokoyama, Manabu Watanabe, Masato Tomomitsu, Kenjiro Aogi
Publikováno v:
Cancer Medicine, Vol 12, Iss 20, Pp 20242-20250 (2023)
Abstract Introduction Pegfilgrastim is indicated to decrease the incidence of chemotherapy‐induced febrile neutropenia. It is the first granulocyte‐colony stimulating factor approved for prophylactic use regardless of carcinoma type and is market
Externí odkaz:
https://doaj.org/article/321b17bf2623432292b885a86ad9cfd3
Autor:
Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17718-17730 (2023)
Abstract Background The role of endocrine therapy in the treatment of patients in a postmenopausal hormonal state and with estrogen receptor (ER)‐positive, human epidermal growth factor receptor 2 (HER2)‐positive advanced or metastatic breast can
Externí odkaz:
https://doaj.org/article/caeec8fc425642ad8dfd47e91b38c921
Autor:
Joanne Chiu, Fei Su, Mukta Joshi, Norikazu Masuda, Takashi Ishikawa, Tomoyuki Aruga, Juan Pablo Zarate, Naveen Babbar, O. Alejandro Balbin, Yoon-Sim Yap
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain relatively limited. Here, we report a longitudinal ctDNA analysis of MONALEESASIA, a phase Ib tr
Externí odkaz:
https://doaj.org/article/5e86dee618714747b7670dcba6041b8f
Autor:
Masaya Hattori, Norikazu Masuda, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Koji Matsumoto, Takashi Ishikawa, Mitsuya Itoh, Hiroyuki Yasojima, Yuko Tanabe, Keiko Yamamoto, Masato Suzuki, Wilbur Pan, Javier Cortes, Hiroji Iwata
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10280-10293 (2023)
Abstract Pembrolizumab plus chemotherapy improved progression‐free survival (PFS) and overall survival (OS) compared with placebo plus chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple‐negative b
Externí odkaz:
https://doaj.org/article/d6b16a26e787415ab7f68851b17b9f97
Autor:
Ken Yoshida, Tadayuki Kotsuma, Yuji Takaoka, Setsuo Tamenaga, Hideya Yamazaki, Takayuki Nose, Naoya Murakami, Koji Inaba, Hironori Akiyama, Koji Masui, Tadashi Takenaka, Hikaru Kubota, Nikolaos Tselis, Norikazu Masuda, Hiroyuki Yasojima, Masashi Takeda, Masayuki Mano, Satoaki Nakamura, Keita Utsunomiya, Noboru Tanigawa, Eiichi Tanaka
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 15, Iss 1, Pp 1-8 (2023)
Externí odkaz:
https://doaj.org/article/22d6836ad62745acac401bc9c0742214
Autor:
Hiroji Iwata, Kenichi Yoshimura, Norikazu Masuda, Kenjiro Aogi, Yuko Tanabe, Koji Matsumoto, Masato Takahashi, Hitomi Sakai, Junji Tsurutani, Chiyo K Imamura, Tsutomu Iwasa, Toshimi Takano, Kiyoshi Yoshimura, Jun Masuda, Manabu Futamura, Mari Hosonaga, Toru Mukohara, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased the effectiveness
Externí odkaz:
https://doaj.org/article/48eaa440eb16414586e7459b2d147b7c
Autor:
Hibiki Udagawa, Shunji Takahashi, Motohiro Hirao, Makoto Tahara, Satoru Iwasa, Yasuyoshi Sato, Takuya Hamakawa, Kohei Shitara, Hidehito Horinouchi, Keisho Chin, Norikazu Masuda, Takuya Suzuki, Shiori Okumura, Takao Takase, Reiko Nagai, Kan Yonemori
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1269-1278 (2023)
Abstract Background In this open‐label, Phase 1 study, we explore the safety and efficacy of E7389‐LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors. Methods This open‐label, Phase 1 study enrolled Japanese
Externí odkaz:
https://doaj.org/article/73b26d485732490b8b8d2a682fc73707